Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

JP3463000004
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BJPPH4
45020
Takeda Pharmaceutical Company Limited
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Takeda Pharmaceutical Company Limited
ISIN
JP3463000004
TICKER
45020
MIC
XJPX
REUTERS
4502.T
BLOOMBERG
4502 JP
Mi., 30.04.2025       Takeda Pharmaceutical
US8740602052

See the full release at Takeda.com View source version on businesswire.com: https://www.businesswire.com/news/home/20250430215346/en/...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
So., 30.03.2025       Takeda Pharmaceutical
US8740602052

Das Instrument TKDA US8740602052 TAKEDA PHARM.SPON.ADR/1/2 EQUITY wird ex Dividende/Zinsen gehandelt am 31.03.2025 The instrument TKDA US8740602052 TAKEDA PHARM.SPON.ADR/1/2 EQUITY has its ex-dividend/interest day on 31.03.2025...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 27.03.2025       Takeda Pharmaceutical
JP3463000004

HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada TORONTO, March 27, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® (normal immunoglobulin [human] 10% and recombinant human hyaluronidase...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 03.03.2025       Takeda Pharmaceutical
US8740602052

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study m...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 24.02.2025       Takeda Pharmaceutical
US8740602052

TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients.In the EU, TAKHZYRO is Approved for Rou...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 24.02.2025       Takeda Pharmaceutical
US8740602052

TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients.In the EU, TAKHZYRO is Approved for Rou...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 24.02.2025       Takeda Pharmaceutical
US8740602052

TAKHZYRO-Injektionslösung in einem 2-ml-Fertigpen ist jetzt zur Erleichterung der subkutanen Verabreichung bei jugendlichen (ab 12 Jahren) und erwachsenen Patienten mit HAE zugelassen.1 Die Option des vorgefüllten Pens wurde entwickelt, um eine individualisierte Behandlung von jugendlichen und erwachsenen HAE-Patienten zu ermöglichen. In der EU i...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 30.01.2025       Takeda Pharmaceutical
JP3463000004

  News Release   Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026   CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process   OSAKA, Japan and CAMBRIDGE, Massachusetts, January 30, 2025 – Takeda (TSE......
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 30.01.2025       Takeda Pharmaceutical
US8740602052

Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. M...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 30.01.2025       Takeda Pharmaceutical
US8740602052

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch Products, which delivered double-digit growth of 14.6% at CER. The company has upgraded its full year outlook for growth, reflecting strong year-to-da...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 30.01.2025       Takeda Pharmaceutical
JP3463000004

Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS) OSAKA, Japan, January 30, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2025 (FY2024), as below.   Revised Forecast for Full Year Consolidated Financials for the Fiscal......
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 29.01.2025       Takeda Pharmaceutical
JP3463000004

TORONTO, Jan. 29, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®– (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) as a replacement therapy for primary humoral immunodeficiency (PI) or secondary humoral immunodeficiency (SI) – to its list...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 21.01.2025       Takeda Pharmaceutical
JP3463000004

Recognition Reinforces Commitment to Creating an Exceptional People Experience TORONTO, Jan. 21, 2025 /CNW/ - Today, Takeda Canada Inc. ("Takeda") announced that, for the third consecutive year, it has received Top Employer® certif...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 20.01.2025       Takeda Pharmaceutical
JP3463000004

Positive Reimbursement Recommendations by Canada's Drug Agency and Institut National d'excellence en Santé et Services Sociaux TORONTO, Jan. 20, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for FRUZAQLA™ (fruquintinib capsules), indicated for the treatment of adult patients...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 27.12.2024       Takeda Pharmaceutical
US8740602052

Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an incr...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 19.12.2024       Takeda Pharmaceutical
JP3463000004

Twenty Canadian Fellows Participate in the Inaugural Program TORONTO, Dec. 19, 2024 /CNW/ - Takeda Canada Inc. (Takeda) is proud to sponsor the Inaugural MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellows Initiative. This program aims to standardize training, organize networks, and implement Entrustable Professional Activities (E...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 12.12.2024       Takeda Pharmaceutical
JP3463000004

Takeda (TSE:4502/NYSE:TAK) will host an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. “We are focused on advancing our innovative pipeline and acceleratin...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 03.12.2024       Takeda Pharmaceutical
JP3463000004

Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. Elritercept is a late-stage investigational activin inhibitor designed to treat a...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 04.11.2024       Takeda Pharmaceutical
JP3463000004

Approximately 300,000 Canadians are living with IBD, with the number projected to grow to 470,000 by 2035.1 TORONTO, Nov. 4, 2024 /CNW/ - Takeda Canada Inc. ("Takeda") announces new data highlighting the impact Inflammatory Bowel Disease (IBD) has on Canadians. The data reveals insights into how the disease affects daily life, the c...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 31.10.2024       Takeda Pharmaceutical
US8740602052

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full year forecasts and Management Guidance to reflect stronger than anticipated first-half performance...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 31.10.2024       Takeda Pharmaceutical
JP3463000004

  News Release Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS) OSAKA, Japan, October 31, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2025 (FY2024), as below.   Revised Forecast for Full Year Consolidated Financia......
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 24.10.2024       Takeda Pharmaceutical
US8740602052

Takeda (TOKYO:4502/NYSE:TAK) and Boston Medical Center (BMC) today announced a new collaboration focused on identifying innovative solutions that can reduce hard-to-abate greenhouse gas (GHG) emissions in the health care sector. The collaboration between Takeda and BMC aims to reduce the GHG emissions caused by disposal of regulated medical waste,...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 25.09.2024       Takeda Pharmaceutical
JP3463000004

Das Instrument TKD JP3463000004 TAKEDA PHARM.CO.LTD. EQUITY wird cum Dividende/Zinsen gehandelt am 26.09.2024 und ex Dividende/Zinsen am 27.09.2024 The instrument TKD JP3463000004 TAKEDA PHARM.CO.LTD. EQUITY has its pre-dividend/interest day on 26.09.2024 and its ex-dividend/interest day on 27.09.2024...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 24.09.2024       Takeda Pharmaceutical
JP3463000004

Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurre...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 19.09.2024       Takeda Pharmaceutical
US8740602052

Takeda (TSE:4502/NYSE:TAK) will present additional data from the Phase 2b trials (TAK-861-2001,TAK-861-2002) and long-term extension (LTE) study (TAK-861-2003) of TAK-861 in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society (ESRS), being held September 24-27, 2024 in...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 18.09.2024       Takeda Pharmaceutical
US8740602052

Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda’s focus on tackling syste...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 16.09.2024       Takeda Pharmaceutical
JP3463000004

Vatroslav Mateljic's innovative approach and commitment to transforming the lives of patients will strengthen Takeda's leadership position in the Canadian biopharmaceutical sectorTORONTO, Sept. 16, 2024 /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Vatroslav (Vatro) Mateljic as its new General Manager to l...
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 09.05.2024       Takeda Pharmaceutical
JP3463000004

OSAKA, Japan, May 9, 2024 – Takeda (TSE:4502/NYSE:TAK) announced that its Board of Directors today approved a significant multi-year program focused on organizational agility, spending efficiencies and leveraging the company’s capabilities in data, digital and technology (DD&T). The program aims to improve growth through continued advancement o......
Zur Nachricht
Takeda Pharmaceutical
Charts & Research Termsheets Terminal
Permalink